We have investigated the ability of lymphocytes from normal subjects and patients with autoimmune thyroid diseases to respond to a thyroidal antigen (human thyroglobulin, hTG) and a non-thyroidal antigen (Keyhole limpet hemocyanin, KLH) in vitro, using a hapten (trinitrophenol, TNP)-carrier system. This system is based on the concept that the T helper cells which respond to hTG or KLH should stimulate anti-TNP antibody producing B cells in the presence of TNP conjugated hTG (TNP-hTG) or KLH (TNP-KLH).
In patients with autoimmune thyroid diseases the occurrence of HLA-DR3 and DR5 antigens is increased (Farid and Bear, 1981) . It is believed that these HLA-DR antigens are associated with genetically determined abnormal immune responses. Many of the patients have a positive family history of these diseases, and children of patients with Graves' disease have a high incidence of auto-antibodies to the thyroid (Carey, et al., 1980) . The basic pathogenesis of autoimmune thyroid diseases could be that patients have a genetic predisposition to respond to thyroid antigens more readily than normals.
Previous studies on the regulation of in vitro anti-human thyroglobulin (hTG) antibody production have suggested both B cell and T cell abnormalities (Beall and Kruger, 1979; McLachlan et al., 1980; Noma et al., 1982) . However in some of these studies allogeneic lymphocytes were mixed (Beall and Kruger, 1979; et al. Endocrinol. Japon. April 1987 McLachlan et al., 1980; Noma et al., 1982) , and possible allogeneic effects (Golding and Rittenberg, 1982; Callard and Smith, 1981; Brenner and Munro, 1981) were not clearly excluded. In other studies nonspecific manipulation of suppressor T cells was employed (Beall and Kruger, 1979; .
In this study we intended to investigate possible regulatory abnormalities in the response of lymphocytes to hTG, a thyroid specific antigen, and to keyhole limpet hemocyanin (KLH), a nonthyroid specific antigen. When we study possible T cell abnormalities altering antibody production, differences in the frequency of hTG specific B cells between patients and normal subjects could cause a problem.
To avoid this problem we used hapten (TNP) conjugates of hTG and KLH, and measured anti-TNP antibody producing B cells. These TNPspecific B cells should be of similar frequency in patients and normal populations. In this system, it has been documented that carrier (hTG or KLH) specific T helper cells or factors can induce hapten (TNP) specific response in B cells, provided the hapten (TNP) is coupled to the original carrier antigen (hTG or KLH) (Dosch et al., 1982; Hei jnen et al., 1981) . Therefore carrier protein specific immune response can be detected by the number of TNP plaques.
Materials and Methods
Thirty patients with autoimmune thyroid disease (24 with Graves', 6 with Hashimoto's disease) and 22 normal controls were tested.
In the patient group, 10 were TGHA positive (> 1: 40) and 20 were negative.
Among patients with Graves' disease, 3 were toxic without treatment, 3 were euthyroid on PTU, and 18 were euthyroid and in remission for more than one year after various treatments. All the patients with Hashimoto's disease had high TGHA titers (>1: 6,400) and were hypothyroid at the time of diagnosis, but were euthyroid when this study was done after replacement with thyroid hormone.
Data about age and sex are shown in Table 1 When the lymphocytes were stimulated by TNP-hTG and PWM, the number of TNP-PFC in normal controls was reduced at higher concentrations of TNP-hTG ( Fig.  2-A) .
Since there was no difference in cell viability among tubes, the reduction of the et al.
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number PFC in normal subjects was not due to a toxic effect of TNP-hTG, but seemed to be related with the induction of suppressor T cells. On the other hand, the number of TNP-PFC in patients was not reduced at higher antigen concentrations and, furthermore, was enhanced at two concentrations (1 and 100 ng/ml)( Fig.2-B) . We then divided the patient group into subgroups on the basis of clinical diagnosis (Fig.2-C, D) , or the presence or absence of anti-hTG autoantibody (TGHA) (Fig.2-E, F) . In patients with Graves' disease who had been in remission for more than one year, there was no reduction in PFC at higher concentration of TNP-hTG (Fig.2-C) , which suggested that the abnormalities were not related to the thyroid function, and that they might be the primary abnormalities in those patients. The enhancement of the response was more demonstrable in patients with Hashimoto's disease (Fig.2-D) or with positive TGHA (Fig.2-F) .
Comparison of the absolute numbers of PFC at each antigen concentration in normal cultures (PWM alone), whereas those with TNP-hTG
were not increased at all. On the other hand, patient PBL showed increased response to both antigens.
Compared to the value for normal controls, the response to TNP-hTG in patients with Hashimoto's disease showed a significant increase, although the response to both antigens in the other groups of patients and patients as a whole did not show a difference. In the patient group, anti-TNP response in the cultures with PWM alone was smaller than that in normal controls. Therefore, the major differences between normal controls and patients were that the patients showed a poor response to PWM alone and a clear and enhanced response to hTG. Several groups have reported on in vitro anti-TNP and -DNP antibody production in humans using TNP or DNP conjugates of different protein antigens or polyacrylamide beads (Dosch et al., 1982; Heijnen et al., 1981; Watanabe et al., 1974; Delfraissy et al., 1977; Morimoto et al., 1981) . T cells are required in this antihapten antibody response, even if the TNP conjugate is in insoluble form.
Furthermore, carrier antigen specific T helper cells and T suppressor cells or their factors (induced in vitro by a low and high dose of antigens, respectively) were shown to regulate the anti-hapten antibody response, provided the hapten is coupled to the original carrier antigens (Dosch et al., 1982; Heijnen et al., 1981) .
Therefore, these systems allow us to investigate regulatory cell (T cells and macrophages) abnormalities in relation to protein antigens through the number of anti-TNP plaques, without concern for the B cell phenomenon related to that antigen. This theoretically has a great advantage in an investigation of regulatory cell abnormalities in autoimmune diseases, in which both B cell and T cell abnormalities have been implicated.
Although this kind of study should be carried out without nonspcific mitogenic stimulants, it was necessary for us to add a low dose of PWM because we could not demonstrate any anti-TNP response without PWM. However, the use of PWM does not prevent our studying the regulatory cell phenomena in relation to carrier antigens, because PWM is primarily a T cell mitogen (Keighthley et al., 1976) and has a synergistic effect with an antigen (Khansaril et al., 1983) .
In the present study, the optimal concentration of TNP conjugate and the number of PFC varied very much from person to person. We analyzed our data in two ways, by the dose response curve (Fig.2, 3, 4) and by maximal response in the cultures with TNP conjugates (Table 1) .
The first finding was that the TNP response in patients to PWM alone was lower than that in normal controls (Table  1) . The general responsiveness of T cells to PWM did not seem to differ between the two groups since other investigators reported that lymphocytes from patients with autoimmune thyroid diseases produced the same magnitude of IgG by stimulation with PWM as normals (McLachlan et al., 1980; , and also, our data about background SRBC-PFC production by the stimulation with PWM alone were similar for both groups. The number in the TNP-specific B cell population also seemed similar since our data for maximal response with antigens were the same for both groups. Therefore, in patients with autoimmune thyroid diseases, TNP-specific helper factor production by PWM alone or TNP-specific B cell responsiveness to that factor might be deficient. However, both possibilities remained to be investigated further.
The second finding was the difference between the response to hTG in normal controls and patients. In normal controls, hTG caused suppression of both TNP and SRBC response, suggesting the induction of non-specific suppressor T cells by hTG. On the other hand, in patients, hTG caused the enhancement of TNP response and no change in SRBC response, suggesting the presence of hTG-specific helper T cells and deficiency in non-specific suppressor T cells. The presence of hTG-specific helper T cells might be related to a lack of specific suppressor T cells.
No matter how the mechanism is, these results demonstrated the presence of regulatory cell abnormalities in patients with autoimmune thyroid diseases. The results that maximal response to hTG in patients with Hashimoto's disease was the highest and significantly higher than normal controls well reflects the clinical observation of their high TGHA titers in the 
